Saturday 17 October 2026 Export PACB’s income statement to Excel — free account

Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.73 0.23 −11.73%

Follow PACB

Alert me

Market cap: $609.2M
P/E: 0.0×
Fwd P/E: −3.5×
Dividend yield: —
F-score: 3/9
Altman Z: −6.04
Beneish M: −5.14
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 3.37

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	3	3	1	—	—	—	1	—	1

Insider Ownership 8.51%

Capital & Financial Ratios $m

Market Cap 609.23

Revenue 159.27

Net Income (131.39)

Free Cash Flow (80.48)

Net Debt 407.43

Current Ratio 4.92

Debt/Equity (19.40)

P/E ratio 0.00

Fwd P/E (3.54)

P/S ratio 3.37

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 74.10%

Next Y EPS Growth 5.00%

Next Y revenue growth (0.82%)

Next 5Y EPS Growth 41.41%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 22.93%

10-year low 10-year high

EV/Sales against its own 10 years 40.99%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	632	391	280	237
Receivables	37	28	35	31
Inventory	57	59	49	61
Other	—	—	—	—
	742	496	375	339

	2023	2024	2025	Q'26
Payables	15	17	21	19
ST’ Debt	—	—	—	—
Other	8	3	2	2
	95	66	73	69

Compound Annual Growth %

	10y	5y	3y
Sales	5.60%	15.19%	7.64%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(23.06%)	(56.30%)	(78.82%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	37	39	—	—	—
’25	37	40	38	45	160
’24	39	36	40	39	154
’23	39	48	56	58	201
’22	33	35	32	27	128
’21	29	31	35	36	131
’20	16	17	19	27	79

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(45)	(36)	—	—	—
’25	(44)	(29)	(19)	(19)	(111)
’24	(76)	(54)	(45)	(31)	(206)
’23	(95)	(42)	(65)	(58)	(259)
’22	(79)	(61)	(63)	(61)	(263)
’21	(23)	(16)	(41)	(32)	(111)
’20	75	(24)	(18)	(14)	20

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(39)	—	—	—
’25	(50)	(30)	(19)	(20)	(119)
’24	(80)	(56)	(45)	(32)	(212)
’23	(98)	(44)	(66)	(60)	(268)
’22	(83)	(65)	(67)	(66)	(280)
’21	(24)	(17)	(42)	(35)	(117)
’20	75	(24)	(18)	(14)	18

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.03)	(0.14)	—	—	—
’25	(1.44)	(0.14)	(0.13)	(0.13)	(1.82)
’24	(0.29)	(0.64)	(0.22)	(0.49)	(1.07)
’23	(0.36)	(0.28)	(0.26)	(0.31)	(1.21)
’22	(0.37)	(0.32)	(0.34)	(0.37)	(1.40)
’21	(0.45)	(0.21)	0.08	(0.31)	(0.89)
’20	0.01	(0.15)	(0.14)	0.37	0.17

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3.76	2.51	2.02	4.37	2.20	18.26	3.85	5.74	1.16	0.85	Analyst estimates 2026–2028 Powerpack
	High	13.98	5.74	7.84	7.50	29.73	53.69	21.01	14.55	9.99	2.73
People
People	Employees	438	456	401	404	412	728	769	796	575	485
	Revenue/emp, $m	0.21	0.20	0.20	0.22	0.19	0.18	0.17	0.25	0.27	0.33
Income, $m
Income, $m	Revenue	91	93	79	91	79	131	128	201	154	160
	Gross margin, %	48.68	37.08	31.92	38.04	41.28	45.10	38.22	26.32	24.21	28.61
	EBT	(74)	(92)	(103)	(84)	29	(275)	(314)	(318)	(310)	(546)
	EBT margin, %	(81.99)	(98.63)	(130.44)	(92.57)	37.27	(210.61)	(244.92)	(158.67)	(200.98)	(341.28)
	Net income	(74)	(92)	(103)	(84)	29	(181)	(314)	(307)	(310)	(546)
	Depreciation	5	10	7	10	9	16	17	14	225	397
Per share, $
Per share, $	Revenue	1.02	0.88	0.58	0.60	0.48	0.64	0.57	0.79	0.56	0.53
	Earnings	(0.83)	(0.87)	(0.76)	(0.55)	0.18	(0.89)	(1.40)	(1.21)	(1.12)	(1.82)
	Cash flow	(0.76)	(0.64)	(0.49)	(0.51)	0.12	(0.54)	(1.17)	(1.02)	(0.75)	(0.37)
	Capex	(0.09)	(0.10)	(0.01)	(0.02)	(0.01)	(0.03)	(0.08)	(0.03)	(0.02)	(0.03)
	Free cash flow	(0.85)	(0.74)	(0.51)	(0.53)	0.11	(0.57)	(1.25)	(1.06)	(0.77)	(0.40)
	Book value	0.95	0.81	0.84	0.36	2.03	3.87	2.51	2.77	1.85	0.02
	Shares, m	89	106	135	153	165	204	225	254	274	300
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	216.17	0.00	0.00	0.00	0.00	0.00
	P/S	4.28	3.15	12.71	8.63	54.31	32.00	13.90	12.13	3.26	3.51
	P/B	4.59	3.42	8.76	14.28	12.77	5.28	3.17	3.47	0.99	104.86
	EV/Sales	3.67	2.63	11.60	8.54	50.74	30.86	14.86	13.43	4.93	5.79
	EV/FCF	(4.37)	(3.15)	(13.36)	(9.57)	216.82	(34.39)	(6.81)	(10.05)	(3.58)	(7.79)
Cash, $m
Cash, $m	Operating cash flow	(68)	(68)	(66)	(78)	20	(111)	(263)	(259)	(206)	(111)
	Capex	(8)	(10)	(2)	(3)	(1)	(6)	(17)	(9)	(6)	(8)
	Free cash flow	(76)	(78)	(68)	(81)	18	(117)	(280)	(268)	(212)	(119)
Balance, $m
Balance, $m	Working capital	75	73	105	32	317	1,029	589	647	429	302
	Total debt	16	14	15	42	38	896	897	892	647	645
	Net debt	(56)	(49)	(88)	(7)	(282)	(149)	124	261	257	366
	Shareholders’ equity	85	86	114	55	335	791	563	701	507	5
Returns, %
Returns, %	ROA	(55.30)	(65.39)	(65.25)	(52.87)	10.46	(14.97)	(16.65)	(17.46)	(20.61)	(53.45)
	ROIC	(154.63)	(152.21)	(239.39)	(132.25)	(121.17)	(20.48)	(27.95)	(21.73)	(38.83)	(93.25)
	ROE	(94.02)	(107.97)	(102.48)	(99.58)	15.06	(32.18)	(46.42)	(48.53)	(51.30)	(213.45)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CTKB Cytek Biosciences, Inc.	$703.2M	— (loss-making)	— (loss-making)	+5.57% (above 0%: growing)	n/m	+42.50% (above 0%: growing)	58.87%	(23.68%)	Compare
PACB Pacific Biosciences of California, Inc.	$609.2M	— (loss-making)	— (loss-making)	−1.91% (below 0%: shrinking)	n/m	−30.97% (below 0%: shrinking)	32.40%	(114.36%)
KIDS OrthoPediatrics Corp.	$589.3M	— (loss-making)	— (loss-making)	+15.43% (above 0%: growing)	n/m	+77.59% (above 0%: growing)	74.27%	(5.77%)	Compare
TCMD Tactile Systems Technology, Inc.	$527.6M	20.5×	22.7×	+8.61% (above 0%: growing)	+142.86% (above 0%: growing)	−86.53% (below 0%: shrinking)	76.25%	7.97%	Compare
SSII SS Innovations International, Inc.	$517.2M	— (loss-making)	— (loss-making)	+39.39% (above 0%: growing)	n/m	−16.62% (below 0%: shrinking)	50.94%	(16.29%)	Compare
DCTH Delcath Systems, Inc.	$513.9M	1,408×	— (loss-making)	+20.60% (above 0%: growing)	−12.50% (below 0%: shrinking)	−24.45% (below 0%: shrinking)	89.75%	8.22%	Compare
MASS 908 Devices Inc.	$491.5M	— (loss-making)	— (loss-making)	+23.31% (above 0%: growing)	n/m	+150.95% (above 0%: growing)	51.90%	(79.69%)	Compare
SGHT Sight Sciences, Inc.	$484.8M	— (loss-making)	— (loss-making)	+19.55% (above 0%: growing)	n/m	+26.71% (above 0%: growing)	91.39%	(16.62%)	Compare
BWAY Brainsway Ltd. Sponsored ADR	$475.8M	24.8×	— (loss-making)	+35.43% (above 0%: growing)	+40.00% (above 0%: growing)	−51.68% (below 0%: shrinking)	74.62%	13.98%	Compare
Median of peers	$515.6M	24.8×	—	+20.07%	+40.00%	+5.05%	74.45%	(11.03%)

All 149 Medical Devices stocks →

Pacific Biosciences of California, Inc. (PACB) key facts

Concern: Pacific Biosciences of California, Inc. reported a net loss of $546.4 million, or a loss of $1.82 per share, for fiscal 2025.
Strength: Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024.
Pacific Biosciences of California, Inc. (PACB) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PACB traded at $1.73, a market capitalization of $609.2 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 3.4× sales.
Return on equity was −213.5% and debt-to-equity -19.40.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −6.04 (distress zone) for fiscal 2025.